

Results of 2022 Annual General Meeting

3 November 2022

In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), we advise details of the resolutions and the proxies received in respect of each resolution as set out in the attached proxy summary.

—ENDS—

Authorised by Melanie Leydin, Company Secretary.

Contacts

Corporate

Melanie Leydin
Company Secretary
companysecretary@4DMedical.com

Media

Julia Maguire
+61 2 8999 3699
julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), the first modality to dynamically quantify ventilation throughout the lungs.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.

ANNUAL GENERAL MEETING
Thursday, 3 November, 2022

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			Result
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	
2	REMUNERATION REPORT	N	23,384,939 89.78%	330,909 1.27%	2,331,924 8.95%	6,026,278	29,217,181 98.88%	330,909 1.12%	6,044,033	Carried
3	ELECTION OF DIRECTOR MS EVONNE COLLIER	NA	30,070,737 92.38%	145,293 0.45%	2,333,666 7.17%	33,992	101,495,513 99.86%	145,293 0.14%	51,747	Carried
4	RE-ELECTION OF DIRECTOR MR JOHN LIVINGSTON	NA	21,966,271 67.58%	8,208,986 25.26%	2,328,086 7.16%	80,345	93,368,145 91.90%	8,226,308 8.10%	98,100	Carried
5	RE-ELECTION OF DIRECTOR MR JULIAN SUTTON	NA	30,004,408 92.30%	171,899 0.53%	2,330,086 7.17%	77,295	100,944,804 99.83%	171,899 0.17%	575,850	Carried
6	GRANT OF OPTIONS TO THE MANAGING DIRECTOR AND CEO	NA	23,330,090 73.37%	6,132,321 19.29%	2,334,953 7.34%	786,324	29,165,361 82.63%	6,132,321 17.37%	804,079	Carried
7	RENEWAL OF THE PROPORTIONAL TAKEOVER APPROVAL PROVISIONS IN THE CONSTITUTION OF COMPANY	NA	27,471,821 91.27%	276,811 0.92%	2,351,057 7.81%	2,483,999	98,913,988 99.72%	276,811 0.28%	2,501,754	Carried
8	APPROVAL OF 10% PLACEMENT CAPACITY	NA	18,443,258 61.25%	9,325,340 30.97%	2,344,574 7.79%	2,470,516	89,875,192 90.58%	9,343,095 9.42%	2,474,266	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item